EHA 2021 | Long-term results from a trial of TAG in patients with BPDCN
Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX, talks on the long-term safety and efficacy of tagraxofusp (TAG) monotherapy in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). TAG is a CD123-directed immunotherapy which received FDA approval for the treatment of BPDCN in 2018 and was also recently approved in the EU. Common treatment-emergent adverse events such as increased alanine and capillary leak syndrome were manageable, and a high rate of complete response allowed bridging of 51% of responders to stem cell transplantation (SCT). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Naveen Pemmaraju, MD, is a member of the ASH Communications Committee and the ASCO Leukemia Advisory panel; has participated in consultancy work for Pacylex Pharmaceuticals, ImmuniGen, Bristol Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US Inc., Triptych Health Partners and CTI Biopharma; has received grants from Affymetrix and SagerStrong Foundation; has received honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media LLC, Aptitude Health, NeoPharm Israel and CareDx, Inc., has received research support from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix, Daiichi Sankyo and Plexxikon; and has received travel reimbursement from Stemline Therapeutics, Celgene, MustangBio, DAVA Oncology and AbbVie.
